Tenax Therapeutics Inc (TENX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Tenax Therapeutics Inc (TENX) has a cash flow conversion efficiency ratio of -0.125x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-14.15 Million) by net assets ($113.59 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see TENX market cap for the company's overall valuation and market capitalisation.
Tenax Therapeutics Inc - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Tenax Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Tenax Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Tenax Therapeutics Inc ranked by their cash flow conversion efficiency. Explore how high is Tenax Therapeutics Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Manuka Resources Ltd
AU:MKR
|
-0.335x |
|
Thai Mitsuwa Public Company Limited
BK:TMW
|
0.023x |
|
Kronox Lab Sciences Ltd
NSE:KRONOX
|
0.090x |
|
Grupe S.A.B. de C.V
MX:CIDMEGA
|
0.023x |
|
Union Auction Public Company Limited
BK:AUCT
|
-0.010x |
|
Optex Systems Holdings, Inc. Common Stock
NASDAQ:OPXS
|
0.084x |
|
Bubs Australia Ltd
AU:BUB
|
-0.127x |
|
Ching Chan Optical Technology Co Ltd
TWO:2070
|
0.017x |
Annual Cash Flow Conversion Efficiency for Tenax Therapeutics Inc (1995–2025)
The table below shows the annual cash flow conversion efficiency of Tenax Therapeutics Inc from 1995 to 2025. View Tenax Therapeutics Inc share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $97.07 Million | $-35.80 Million | -0.369x | -129.07% |
| 2024-12-31 | $91.99 Million | $-14.81 Million | -0.161x | +77.92% |
| 2023-12-31 | $8.10 Million | $-5.90 Million | -0.729x | +90.94% |
| 2022-12-31 | $1.49 Million | $-12.01 Million | -8.048x | -214.65% |
| 2021-12-31 | $4.24 Million | $-10.86 Million | -2.558x | -27.58% |
| 2020-12-31 | $4.63 Million | $-9.27 Million | -2.005x | -0.09% |
| 2019-12-31 | $3.77 Million | $-7.56 Million | -2.003x | -328.73% |
| 2018-12-31 | $11.77 Million | $-5.50 Million | -0.467x | +65.82% |
| 2017-12-31 | $8.88 Million | $-12.14 Million | -1.367x | -47.62% |
| 2016-12-31 | $17.14 Million | $-15.87 Million | -0.926x | -473.89% |
| 2015-12-31 | $60.42 Million | $-9.75 Million | -0.161x | -44.39% |
| 2014-12-31 | $82.89 Million | $-9.26 Million | -0.112x | 0.00% |
| 2013-12-31 | $82.89 Million | $-9.26 Million | -0.112x | +31.20% |
| 2012-12-31 | $30.30 Million | $-4.92 Million | -0.162x | -101.68% |
| 2011-12-31 | $-871.46K | $-8.40 Million | 9.643x | +338.84% |
| 2010-12-31 | $2.13 Million | $-8.59 Million | -4.037x | -281.02% |
| 2009-12-31 | $3.83 Million | $-4.06 Million | -1.060x | -207.36% |
| 2008-12-31 | $6.60 Million | $-2.28 Million | -0.345x | -113.89% |
| 2007-12-31 | $-458.25K | $-1.14 Million | 2.483x | +121.52% |
| 2006-12-31 | $186.22K | $-2.15 Million | -11.537x | -449.29% |
| 2005-12-31 | $948.40K | $-1.99 Million | -2.100x | -71.48% |
| 2004-12-31 | $1.45 Million | $-1.77 Million | -1.225x | +32.60% |
| 2003-12-31 | $1.15 Million | $-2.09 Million | -1.817x | -18.33% |
| 2002-12-31 | $1.24 Million | $-1.90 Million | -1.536x | -239.02% |
| 2001-12-31 | $3.39 Million | $-1.54 Million | -0.453x | -190.35% |
| 2000-12-31 | $5.85 Million | $-913.30K | -0.156x | -101.95% |
| 1999-12-31 | $-100.00K | $-800.00K | 8.000x | +588.53% |
| 1998-12-31 | $351.55K | $-575.69K | -1.638x | -153.05% |
| 1997-12-31 | $-282.51K | $-872.15K | 3.087x | +20.56% |
| 1996-12-31 | $-597.60K | $-1.53 Million | 2.561x | 0.00% |
| 1995-12-31 | $-597.60K | $-1.53 Million | 2.561x | -- |
About Tenax Therapeutics Inc
Tenax Therapeutics, Inc., a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States. It develops TNX-101, TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension in heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imat… Read more